Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases; a license agreement with City of Hope; and a licensing and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of medicines in the areas of cardio-metabolic disease, neurodegeneration, and pain. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DRNA
Previous Symbol
CUSIPN/A
Phone617-621-8097
Debt
Debt-to-Equity RatioN/A
Current Ratio6.30
Quick Ratio6.30
Price-To-Earnings
Trailing P/E Ratio-3.48
Forward P/E Ratio-11.08
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.28 million
Price / Sales350.52
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.96 per share
Price / Book6.50
Profitability
EPS (Most Recent Fiscal Year)($3.66)
Net Income$-60,040,000.00
Net Margins-1,418.01%
Return on Equity-63.24%
Return on Assets-51.85%
Miscellaneous
Employees44
Outstanding Shares62,730,000
Market Cap$799.21 million
OptionableOptionable
Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its quarterly earnings results on Monday, November, 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.11. The biopharmaceutical company had revenue of $1.55 million for the quarter, compared to analysts' expectations of $1.67 million. Dicerna Pharmaceuticals had a negative return on equity of 63.24% and a negative net margin of 1,418.01%. View Dicerna Pharmaceuticals' Earnings History.
When is Dicerna Pharmaceuticals' next earnings date?
What price target have analysts set for DRNA?
9 brokers have issued 12-month price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $14.50 to $30.00. On average, they anticipate Dicerna Pharmaceuticals' stock price to reach $21.3125 in the next year. This suggests a possible upside of 67.3% from the stock's current price. View Analyst Price Targets for Dicerna Pharmaceuticals.
What is the consensus analysts' recommendation for Dicerna Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dicerna Pharmaceuticals.
Has Dicerna Pharmaceuticals been receiving favorable news coverage?
News headlines about DRNA stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include Ligand Pharmaceuticals (LGND), Agios Pharmaceuticals (AGIO), Intercept Pharmaceuticals (ICPT), Evotec (EVTCY), Akcea Therapeutics (AKCA), Ascendis Pharma A/S (ASND), Allakos (ALLK), Endo International (ENDP), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Myokardia (MYOK), ACADIA Pharmaceuticals (ACAD), Global Blood Therapeutics (GBT), Xencor (XNCR) and Heron Therapeutics (HRTX).
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 49)
- Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 53)
- Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 65)
- Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory Board
- Prof. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 71)
Who are Dicerna Pharmaceuticals' major shareholders?
Dicerna Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include EcoR1 Capital LLC (6.06%), BlackRock Inc. (4.73%), Vanguard Group Inc. (3.16%), Citadel Advisors LLC (3.11%), FMR LLC (1.77%) and Emerald Advisers Inc. PA (1.57%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Brian K Halak, Dennis Langer and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.
Which institutional investors are selling Dicerna Pharmaceuticals stock?
DRNA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bridgeway Capital Management Inc., BlueMountain Capital Management LLC, TIAA CREF Investment Management LLC and Credit Suisse AG. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Brian K Halak, Dennis Langer and James B Weissman. View Insider Buying and Selling for Dicerna Pharmaceuticals.
Which institutional investors are buying Dicerna Pharmaceuticals stock?
DRNA stock was acquired by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Vanguard Group Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers Inc. PA, BlackRock Inc., Candriam Luxembourg S.C.A., Citadel Advisors LLC and Monashee Investment Management LLC. View Insider Buying and Selling for Dicerna Pharmaceuticals.
How do I buy shares of Dicerna Pharmaceuticals?
Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of DRNA stock can currently be purchased for approximately $12.74.
How big of a company is Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has a market capitalization of $799.21 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.
What is Dicerna Pharmaceuticals' official website?
How can I contact Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]
MarketBeat Community Rating for Dicerna Pharmaceuticals (NASDAQ DRNA)
MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
